BTKi Role in CLL
Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions

Released: November 09, 2022

Expiration: November 08, 2023

Farrukh Awan
Farrukh Awan, MD, MS
Nicole Lamanna
Nicole Lamanna, MD

Activity

Progress
1
Course Completed

In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:

  • Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today
  • Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy
  • Approval of ibrutinib/venetoclax combination therapy for patients with CLL
  • Key differences between zanubrutinib and acalabrutinib in the treatment of patients with CLL
  • How to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitor